Navigation Links
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Date:10/26/2010

integrated set of capabilities in antibody-based product development.  The company has generated a proprietary pipeline of innovative product candidates by leveraging its three core technology platforms. These proprietary platforms include: (1) cancer stem-like cells; (2) DART technology, which allows the company to incorporate multiple specificities within a single molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions.  The company's lead program, teplizumab, is an anti-CD3 antibody.  Teplizumab is being investigated in Phase 3 trials for the treatment of autoimmune diseases in collaboration with Eli Lilly and Company.  For more information about MacroGenics, please visit www.macrogenics.com.

About Boehringer IngelheimThe Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies.  Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees.  Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.

For more information about Boehringer Ingelheim, please visit www.boehringer-ingelheim.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking
'/>"/>

SOURCE Boehringer Ingelheim; MacroGenics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
2. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
3. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
4. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
5. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
6. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
7. Boehringer Ingelheim Unveils Diabetes Pipeline
8. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
9. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
10. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
11. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "China Orthopedic Instrument Industry Report, 2014-2017" report to ... population and rising proportion of reimbursement for medical expenses, ... released, with its scale presenting a CAGR of 19.2% ... are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... CB1,antagonist rimonabant to show benefits beyond weight reduction ... | March 08, 2007 | The Business Intelligence,firm ... antagonist Acomplia (rimonabant) has at least,five competitors in ... more,in earlier phases of R&D. While Acomplia received ...
... March, 9, 2007-Active Biotech (ACTI.ST), today,announced new positive clinical ... treatment of prostate cancer. , By step-wise dose escalation, ... which corresponds to a doubling of the previously,reported maximum ... a step-wise intra-patient dose-escalation enables a dose,of 1 mg/day ...
Cached Medicine Technology:Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 2Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 3Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer 2
(Date:8/31/2014)... Sunday 31 August 2014: Mortality and morbidity ... year despite good use of oral anticoagulants, according to ... General Pilot Registry. The findings were presented for the ... chairperson Professor Gregory Lip (Birmingham, UK). , Professor Lip ... focused on management practices of European cardiologists conducted since ...
(Date:8/30/2014)... Sunday 31 August 2014: A new batteryless cardiac ... by heart motion was presented at ESC Congress ... prototype device does not require battery replacement. , ... Engineering Group at ARTORG, University of Bern, Switzerland, ... medical implants. Once they reach a critically low ...
(Date:8/30/2014)... In a world where a typical response to conflict ... launches a game app to teach another way. Launched ... app is a colorful way to encourage moral values playfully. ... pulls double-duty by teaching players new ways to find happiness ... gamers for consistently taking the high road, the Ultimate Karma ...
(Date:8/30/2014)... August 31, 2014 Atlanta based automotive ... to help raise money and awareness for ALS by ... General Managers, staff, and even Vice President Jimmy Ellis ... film and can be viewed on their Youtube page; ... the challenge, general managers and staff also took the ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 The ... modeling the body that will reveal to users some shocking ... lead to great results in modeling looks, as well as ... the new method says that there is one unique trick ... new method indicates that despite what many people might think, ...
Breaking Medicine News(10 mins):Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:Newly Launched Ultimate Karma App Elicits Happiness in Players and Encourages Moral Values 2Health News:Jim Ellis Automotive Group Take the ALS Ice Bucket Challenge 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2
... 30 Physicians Healthcare,Management Group, Inc. (Phyhealth) (Pink Sheets: ... with physicians,today announced that its board of directors has ... of the Company,s outstanding Common Stock., The shares ... market price.,The purchases will be made at the Company,s ...
... (Logo: http://www.newscom.com/cgi-bin/prnh/20050825/CLTH069LOGO ), What: HCA ... 2008 @ 9:00 am CT, Where: http://www.videonewswire.com/event.asp?id=52343 , ... log on to the web at the ... HCA Healthcare, 615-344-2688, ...
... /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ("China Sky ... ), a,leading fully integrated pharmaceutical company producing over-the-counter,drugs ... today that it,recently obtained production approval from the ... two of its newly developed drugs., Sodium ...
... ANGELES, Oct. 30 Cardo Medical, a company ... the FDA 510k,clearance of its Align 360 Total ... planned for commercial release during the second quarter ... the flagship product within,its Align 360 platform which ...
... at 1:30 p.m. (Pacific); ... http://www.adventrx.com , SAN DIEGO, Oct. 30 ADVENTRX Pharmaceuticals,Inc. ... conference call with,simultaneous webcast to discuss third quarter 2008 results on ... Mark N. K.,Bagnall, Executive Vice President and Chief Financial Officer, is ...
... and David,Simon, M.D. in Southern California helps people find relief from stress ... ... investments., SAN DIEGO, Oct. 30 As ... life savings,The Chopra Center for Wellbeing is teaching those impacted how to ...
Cached Medicine News:Health News:Phyhealth Announces Stock Buyback Program 2Health News:Phyhealth Announces Stock Buyback Program 3Health News:China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs 2Health News:Cardo Medical Announces FDA Clearance of the Align 360 Total Knee System 2Health News:Cardo Medical Announces FDA Clearance of the Align 360 Total Knee System 3Health News:Turbulent Times Turn The Chopra Center Into Mecca for Calm 2
... The Leica M520 OH3 ... the best optical performance available ... innovative and unique stand. The ... lightest, has the greatest range ...
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
PS Medical lumboperitoneal catheter systems are designed to divert CSF from the lumbar subarachnoid space to the peritoneal cavity, using simplified surgical techniques....
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Medicine Products: